Added to YB: 2026-09-09
Pitch date: 2026-09-07
IRD [neutral]
Opus Genetics, Inc.
-4.13%
current return
Author Info
No bio for this author
Company Info
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders.
Market Cap
$388.5M
Pitch Price
$4.53
Price Target
N/A
Dividend
N/A
EV/EBITDA
-6.64
P/E
-3.61
EV/Sales
34.08
Sector
Biotechnology
Category
special_situation
Week Ahead - Opus Genetics, Inc.
IRD (quick overview): Opus Genetics faces a signal-generating checkpoint with three-month Cohort 1 data from the Phase 1/2 BIRD-1 trial of OPGx-BEST1, targeted for the second week of September. The key question is whether safety and early efficacy support dose escalation and preserve confidence in its seven-program AAV pipeline; a messy safety result could raise platform-level concerns. Cash plus potential note funding is guided to support operations into 2029.
Read full article (1 min)